On this page
MTRR
5-methyltetrahydrofolate-homocysteine methyltransferase reductase
The MTRR gene provides instructions for an enzyme called methionine synthase reductase, which is essential for the proper function of methionine synthase in amino acid metabolism. MTRR codes for an enzyme critical in the metabolic pathway that converts homocysteine to methionine.
MTRR is located on the short (p) arm of chromosome 5, at band 5p15.31. Arm ratio per GRCh38 - banding schematic.
Explore chromosome 5 in the library →Available at Jeen Health
Clinical tests that include this
Overview
The MTRR gene, also known as 5-methyltetrahydrofolate-homocysteine methyltransferase reductase, plays a vital role in cellular metabolism. It produces an enzyme that is necessary for the activity of methionine synthase, another key enzyme in the processing of amino acids. Specifically, MTRR helps reactivate methionine synthase, enabling it to continue converting homocysteine into methionine.
Disruptions to MTRR function can impact this critical metabolic pathway, leading to an accumulation of homocysteine and affecting methionine production. This can have broader implications for health, particularly in metabolic and neurological processes.
What the gene does
The MTRR gene directs the synthesis of methionine synthase reductase, an enzyme crucial for the folate-dependent one-carbon metabolism pathway. This enzyme's primary role is to ensure the continuous activity of methionine synthase. Methionine synthase is responsible for converting the amino acid homocysteine to methionine, a process vital for protein synthesis and other metabolic functions.
After a period of activity, methionine synthase can become inactive. Methionine synthase reductase acts by reactivating this enzyme, essentially 'recharging' it so it can continue its role in amino acid conversion. Without functional methionine synthase reductase, methionine synthase cannot efficiently perform its task, leading to metabolic imbalances such as elevated homocysteine levels and reduced methionine. This pathway is fundamental for maintaining proper cellular function, especially in the nervous system.
Video: Genetics 101
Chromosome location
The MTRR gene is located on chromosome 5, specifically at position 5p15.31. This means it resides on the short (p) arm of chromosome 5, within band 15.31. The precise location on the chromosome helps in understanding its genomic context and potential interactions with other genes in the region.
Protein structure
The MTRR protein, methionine synthase reductase, is composed of 698 amino acids. It features distinct functional regions important for its enzymatic activity. These include a Flavodoxin-like domain spanning amino acids 5-147, which is often involved in binding flavin cofactors. A Hinge region is located between amino acids 166-247, providing flexibility. Additionally, an FAD-binding FR-type domain is found from amino acids 271-533, which is critical for binding the flavin adenine dinucleotide (FAD) cofactor essential for the enzyme's reductase function.
Key variants
Genetic variations within the MTRR gene can affect the enzyme's structure and function. Some variants might alter single amino acids in the protein, while others could lead to the production of a shortened, non-functional enzyme. These changes can disrupt the gene's ability to produce an effective methionine synthase reductase, impairing its role in the metabolic pathway. The impact of these variants can range from mild to severe, depending on how significantly they affect enzyme activity. For instance, the A66G variant involves a substitution of adenine with guanine in the DNA sequence [PMID:16299066].
Sample of pathogenic variants
10 pathogenic / likely-pathogenic variants from ClinVar, ranked by review status (expert-panel-reviewed first). This is a sample; recurrent founder variants in a specific population may not appear here - see the full ClinVar listing via the link above.
| Variant (HGVS) | Protein change | Classification | Evidence | Associated condition |
|---|---|---|---|---|
c.1129C>T | p.Arg377Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblE |
c.1373C>G | p.Ser458Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblE |
c.1418_1419del | p.Val473fs | Pathogenic/Likely pathogenic | ★★☆☆ | Neural tube defects, folate-sensitive |
c.1475G>A | p.Trp492Ter | Pathogenic/Likely pathogenic | ★★☆☆ | Neural tube defects, folate-sensitive |
c.1554_1557+3del | - | Pathogenic/Likely pathogenic | ★★☆☆ | MTRR-related disorder |
c.1674dup | p.Arg559Ter | Pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblE |
c.1677-1G>A | - | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblE |
c.1953-6_1953-2del | - | Pathogenic/Likely pathogenic | ★★☆☆ | Neural tube defects, folate-sensitive |
c.354_358del | p.Gly119fs | Pathogenic/Likely pathogenic | ★★☆☆ | MTRR-related disorder |
c.701dup | p.Leu235fs | Pathogenic/Likely pathogenic | ★★☆☆ | Methylcobalamin deficiency type cblE |
Evidence stars indicate ClinVar review status. Individual variant interpretation should always be performed by a qualified clinical laboratory - many variants remain classified as Variants of Uncertain Significance (VUS) pending more research.
Associated conditions
Variants in the MTRR gene are primarily associated with homocystinuria, an inherited metabolic disorder [PMID:16299066]. This condition is characterised by elevated levels of homocysteine in the blood and urine, resulting from the impaired conversion of homocysteine to methionine. Over 20 different MTRR gene alterations have been identified in individuals with homocystinuria. These changes can range from single amino acid substitutions to mutations that cause the production of a truncated, non-functional enzyme [PMID:16299066]. Such genetic changes can lead to a range of health issues affecting multiple organ systems due to metabolic imbalance.
No condition pages are linked to this gene yet. This does not mean it has no associated conditions.
Inheritance pattern
Conditions caused by pathogenic MTRR variants typically follow autosomal recessive inheritance.
When both parents are carriers, each child has a 25% chance of being affected, 50% of being a carrier, and 25% of being unaffected.
UK clinical status
The MTRR gene is recognised in the UK's National Health Service (NHS) Genomic Medicine Service. It is included on several NHS Genomic Test Directory panels, indicating its clinical relevance for diagnostic testing. MTRR is currently listed as 'green' on panels such as Cytopenias and congenital anaemias, DDG2P, Intellectual disability, Likely inborn error of metabolism (R98), Rare anaemia (R92), and Undiagnosed metabolic disorders, signifying sufficient evidence for its association with these conditions.
Sources: NHS GMS PanelApp · Genomics England PanelApp · NHS National Genomic Test Directory
Frequently asked questions
What is the main function of the MTRR gene?
The MTRR gene provides instructions for making methionine synthase reductase, an enzyme that reactivates methionine synthase. This reactivation is crucial for methionine synthase to convert homocysteine into methionine, a key step in amino acid metabolism.
What health condition is most commonly associated with MTRR gene variants?
Variants in the MTRR gene are most commonly associated with homocystinuria. This condition involves the accumulation of homocysteine due to impaired metabolic conversion, which can affect various bodily systems.
How does MTRR relate to amino acid metabolism?
MTRR is indirectly involved in amino acid metabolism by enabling methionine synthase to function properly. Methionine synthase converts homocysteine, an amino acid, into methionine, another essential amino acid. MTRR's role is to ensure methionine synthase remains active.
References
- Guéant-Rodriguez RM, Rendeli C, Namour B. Transcobalamin and methionine synthase reductase mutated polymorphisms aggravate the risk of neural tube defects in humans. Neuroscience letters. 2003. PMID: 12812837
- Vilaseca MA, Vilarinho L, Zavadakova P. CblE type of homocystinuria: mild clinical phenotype in two patients homozygous for a novel mutation in the MTRR gene. Journal of inherited metabolic disease. 2003. PMID: 12971424
- Carmel R, Green R, Rosenblatt DS. Update on cobalamin, folate, and homocysteine. Hematology. American Society of Hematology. Education Program. 2003. PMID: 14633777
- Doolin MT, Barbaux S, McDonnell M. Maternal genetic effects, exerted by genes involved in homocysteine remethylation, influence the risk of spina bifida. American journal of human genetics. 2002. PMID: 12375236
- Zavadakova P, Fowler B, Zeman J. CblE type of homocystinuria due to methionine synthase reductase deficiency: clinical and molecular studies and prenatal diagnosis in two families. Journal of inherited metabolic disease. 2002. PMID: 12555939
- Hobbs CA, Sherman SL, Yi P. Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome. American journal of human genetics. 2000. PMID: 10930360
- Wilson A, Leclerc D, Rosenblatt DS. Molecular basis for methionine synthase reductase deficiency in patients belonging to the cblE complementation group of disorders in folate/cobalamin metabolism. Human molecular genetics. 1999. PMID: 10484769